Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Polycystic Ovary Syndrome 7Neoplasms 6Breast Neoplasms 6Vomiting 2Solid Tumors 2Skin Neoplasms 2Neoplasm Metastasis 2Melanoma 2Diabetes Mellitus 2Weight Gain 1Venous Thromboembolism 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1Skin Toxicity 1Renal Insufficiency 1Prostatic Neoplasms 1Primary Myelofibrosis 1Premature Birth 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-Eclampsia 1Polycythemia Vera 1Parathyroid Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Nausea 1Myeloproliferative Disorders 1Multiple Myeloma 1

Interventions

Carboplatin 27Paclitaxel 23Cisplatin 22Gemcitabine 17pembrolizumab 15Fluorouracil 9Pemetrexed 8Everolimus 8Docetaxel 8Cetuximab 8Radiotherapy, Intensity-Modulated 7Radiotherapy 7130-nm albumin-bound paclitaxel 7Sorafenib 6Nivolumab 6Bevacizumab 6Axitinib 6epothilone B 5Sunitinib 5Radiation 5Panitumumab 5Cyclophosphamide 5trebananib 4reolysin 4padeliporfin 4lenvatinib 4Irinotecan 4Gefitinib 4vosaroxin 3volociximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma × Tablets × Clear all
NCT00941863 2016-03-22

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Bayer

Phase 1 Completed
158 enrolled 17 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡